Impact of transferrin saturation on cardiovascular events in non-dialysis-dependent chronic kidney disease patients treated with darbepoetin alfa
2024

Impact of Transferrin Saturation on Heart Events in CKD Patients

Sample size: 1040 publication 10 minutes Evidence: high

Author Information

Author(s): Kentaro Nakai, Tomoya Nishino, Tatsuo Kagimura, Ichiei Narita

Primary Institution: Japanese Red Cross Fukuoka Hospital

Hypothesis

Is there an association between transferrin saturation and cardiovascular events in non-dialysis-dependent chronic kidney disease patients treated with darbepoetin alfa?

Conclusion

Higher transferrin saturation levels are associated with fewer cardiovascular events in CKD patients treated with erythropoiesis-stimulating agents.

Supporting Evidence

  • Patients with transferrin saturation ≥30% had a significantly better prognosis.
  • Adjusted hazard ratio for cardiovascular events in patients with transferrin saturation 30-40% was 0.33.
  • Transferrin saturation levels of 30-40% were associated with lower cardiovascular event rates.

Takeaway

If you have kidney problems and get treated for anemia, having more iron in your blood can help keep your heart healthy.

Methodology

This was a multicenter, prospective, observational study evaluating 1040 CKD patients treated with darbepoetin alfa for 96 weeks.

Potential Biases

Potential biases may arise from the observational nature of the study and the reliance on existing clinical data.

Limitations

The study was observational and not a randomized controlled trial, which may limit the strength of the conclusions.

Participant Demographics

Mean age was 69.9 years, with 58.8% male; the study included patients with non-dialysis-dependent CKD.

Statistical Information

P-Value

p<0.001

Confidence Interval

0.22–0.52

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1007/s40620-024-02000-y

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication